Brought to you by:
Nitinol stents placed in iliac veins “not associated with prolonged back pain,” study finds
In a retrospective review of over 600 patients who underwent iliac vein stent placement, the development of back pain was found to be unrelated to stent type, diameter, length or covered vein territory. Chloe Snow (Greenbelt, USA) and colleagues share…
First patient enrolled in HERCULES randomized trial comparing ESAR and EVAR
The first patient has been enrolled into the HERCULES trial, which compares endosuture aneurysm repair (ESAR) to standard endovascular aneurysm repair (EVAR) in the treatment of abdominal aortic aneurysms (AAAs) with wide proximal necks. HERCULES is an investigator-driven trial led by Michel Reijnen, MD,…
TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of SurVeil DCB
Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics’ TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18 November, New York, USA). The TRANSCEND trial is a prospective, multicentre, single-blind randomised controlled trial to…
First patient treated in global strategic collaboration involving Cydar Maps technology
Cydar Medical has announced the successful treatment of the first patient in a strategic collaboration with Medtronic. The collaboration, which spans 40 sites across the U.S., UK and Europe, involves the integration of the company’s Cydar Maps software with Medtronic’s…
The top 10 most popular Vascular Specialist stories of January 2023
In January 2023, most popular among the Vascular Specialist readers were several stories from the recent Southern Association for Vascular Surgery meeting, including a report of data shared to demonstrate the benefits of vascular involvement in non-vascular-led cases; an update on the use of the Human Acellular…
VQI study leader highlights virtue of multispecialty gathering of best longitudinal data on PAD procedures
Daniel Bertges, MD, talks to Vascular Specialist about recent findings from his work investigating the IN.PACT Admiral drug-coated balloon (DCB). He related how they showed promising results in treating femoropopliteal in-stent restenosis in a Society for Vascular Surgery (SVS) Vascular…
Medtronic announces first enrollment in head-to-head global randomized trial evaluating durability of EVAR
Medtronic has announced the first patient enrollment in the ADVANCE trial, a head-to-head randomized controlled trial of two leading aortic stent graft systems, the Medtronic Endurant II/IIs stent graft system and Gore Excluder abdominal aortic aneurysm (AAA) device family systems.…
SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND
In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated “excellent efficacy and safety” out to 24-month follow-up. This is according to Kenneth Rosenfield, MD, from Massachusetts General Hospital in Boston, who presented the new data at Vascular…
Abre stent data show ‘struggle to maintain patency’ among post-thrombotic syndrome patients
The Abre venous stent demonstrated three-year primary patency rates of 97.1%, 76.5% and 70.4% respectively for non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (DVT), and post-thrombotic syndrome (PTS) patient populations within the ABRE clinical study, a late-breaking session…
ABRE clinical study 36-month data show ‘long-term durability’ of venous stent system
Medtronic has announced the 36-month final results from the ABRE clinical study. The purpose of the ABRE clinical study was to evaluate the safety and effectiveness of the company’s Abre venous self-expanding stent system, intended for the treatment of symptomatic iliofemoral…